NCT05411094 - Testing the Safety of the Anti-Cancer Drugs Durvalumab and Olaparib During Radiation Therapy for Locally Advanced Unresectable Pancreatic Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 22, 2023

Primary Completion Date

July 1, 2026

Study Completion Date

July 1, 2028

Conditions

Locally Advanced Pancreatic CarcinomaStage II Pancreatic Cancer AJCC v8Stage III Pancreatic Cancer AJCC v8Unresectable Pancreatic Carcinoma

Interventions

PROCEDURE

Biopsy Procedure

Undergo biopsy

PROCEDURE

Biospecimen Collection

Undergo collection of blood and buccal samples

PROCEDURE

Computed Tomography

Undergo CT scan

BIOLOGICAL

Durvalumab

Given IV

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

DRUG

Olaparib

Given PO

Trial Locations (11)

27599

RECRUITING

UNC Lineberger Comprehensive Cancer Center, Chapel Hill

43210

RECRUITING

Ohio State University Comprehensive Cancer Center, Columbus

48109

RECRUITING

University of Michigan Comprehensive Cancer Center, Ann Arbor

48116

SUSPENDED

University of Michigan - Brighton Center for Specialty Care, Brighton

53718

RECRUITING

University of Wisconsin Carbone Cancer Center - Eastpark Medical Center, Madison

53792

RECRUITING

University of Wisconsin Carbone Cancer Center - University Hospital, Madison

90033

RECRUITING

Los Angeles General Medical Center, Los Angeles

RECRUITING

USC / Norris Comprehensive Cancer Center, Los Angeles

92612

RECRUITING

UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine

92868

RECRUITING

UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange

M5G 2M9

RECRUITING

University Health Network-Princess Margaret Hospital, Toronto

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH